ECE1 Knockout MES-OV Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of MES-OV ovarian carcinoma cells with disrupted ECE1 gene function. This heterogeneous cell pool provides a loss-of-function model for studying endothelin-converting enzyme 1 without clonal selection, mitigating clone-specific artifacts.
The polyclonal format ensures genetic diversity suitable for robust functional analyses of ECE1-mediated peptide processing and oncogenic signaling.
MES-OV is an epithelial cell line derived from human ovarian endometrioid adenocarcinoma, retaining molecular features of ovarian cancer, including expression of endothelin axis components ECE1, endothelin-1, and endothelin receptors. These cells exhibit anchorage-independent growth and tumorigenic potential, serving as a clinically relevant model for ovarian adenocarcinoma biology.
The native endothelin signaling environment in MES-OV cells provides an authentic context to investigate autocrine/paracrine ECE1-dependent pathways in tumor progression and metastasis.
ECE1 encodes a membrane-bound zinc metalloprotease that converts big endothelin-1 into active endothelin-1, a potent vasoconstrictor and mitogen. Endothelin-1 binds G protein-coupled receptors ETA (EDNRA) and ETB (EDNRB), coupling primarily to G??q to activate phospholipase C, triggering calcium mobilization and protein kinase C signaling.
Receptor activation also recruits ??-arrestin-1 and ??-arrestin-2, scaffolding MAPK1/3 and AKT pathways independently of G proteins. Upstream regulators in the tumor milieu??hypoxia, TNF-??, TGF-??, shear stress??modulate ECE1 expression, positioning this enzyme as a critical checkpoint controlling endothelin-driven MAPK and ??-arrestin cascades that govern proliferation, migration, and survival.
In MES-OV ovarian cancer cells, the ECE1/endothelin-1/ETAR axis promotes proliferation, invasion, and angiogenesis, partly via transactivation of growth factor receptors and MAPK1/3 signaling.
Autocrine endothelin-1 production sustains oncogenic loops and modulates the tumor microenvironment. ECE1 disruption in these polyclonal knockout cells is expected to halt endothelin-1 maturation, uncoupling receptor activation and enabling dissection of ECE1??s direct contributions to cell-autonomous tumor phenotypes versus stromal interactions. This model also permits study of compensatory processing pathways and the role of alternative proteases in endothelin peptide generation.
Applications include western blotting to confirm ECE1 loss and assess phosphorylation of MAPK1/3 and AKT; RT-qPCR and ELISA to quantify endothelin-1 and receptor expression; functional assays for proliferation, migration, and invasion. Calcium flux analyses evaluate G??q?CPLC?CIP3 signaling, while phospho-signaling profiling addresses ??-arrestin?Cmediated pathway activation. These cells are valuable for drug validation of endothelin receptor antagonists and ECE1 inhibitors, and for exploring hypoxia-induced angiogenesis, chemoresistance, and tumor-stroma crosstalk. For technical inquiries, contact Ascent Research.
